NCT05199272: A Phase 1 Study of 23ME-00610 in Patients With Advanced Solid Malignancies

NCT05199272
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Other

Key Eligibility Criteria:

Gender: All
Age: 12 Years and older (Child, Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with uncontrolled or symptomatic CNS (central nervous system) metastases; Patients with leptomeningeal disease
https://ClinicalTrials.gov/show/NCT05199272

Comments are closed.

Up ↑